Historical source archive · Canine · Descriptive real-world evidence
Oxyglobin Case Listing Book II: 885 historical canine reports in context
Between December 1998 and August 1999, Biopure received 885 veterinary reports describing Oxyglobin use in anemic dogs. The archive spans hemorrhage, surgery, trauma, immune-mediated hemolysis, parasitic anemia, toxicities, neoplasia, bone-marrow disease and renal failure. Its most useful lesson is not that one product reproduced blood. It is that oxygen-carrying support was repeatedly used as a bridge while definitive treatment addressed the cause.
Evidence boundary: historical manufacturer-collected case reports. Canine, product-specific and descriptive. Records may be incomplete, duplicated across categories and influenced by reporting and selection bias. They are not evidence of BHOC efficacy, approval in another species or current Oxyglobin availability.
Structured case index
Search all 146 printed forms.
Filter by diagnosis, treatment sequence, dose and outcome; open a record for the full structured summary.
Interactive case explorerExplore all 146 cases →
Source identity
One booklet. Three different evidence layers.
The source is Oxyglobin Solution - Case Listing Book II, published by Biopure Corporation and printed in October 2000. The working archive filename has been clarified, but the original bibliographic title is preserved here.
| Layer | What it contains | Correct status |
|---|---|---|
| Utilization summary | 885 reports, clinical categories and reported use with or without blood. | Historical descriptive real-world archive. |
| Printed selection | 146 canine vignettes with diagnosis, PCV, treatment sequence, short follow-up and comments. | Selected uncontrolled case reports. |
| Prescribing information | Historical label plus summaries of a laboratory study and a controlled field trial. | Product-specific regulatory material; controlled claims should be verified against the FDA source. |
Clinical map
What the 885 reports can show.
The booklet groups reported use into blood loss, hemolysis and ineffective erythropoiesis. Within those domains it lists surgery, trauma, rodenticide toxicity, parasitism, ulcers, immune-mediated hemolysis, drug or zinc toxicity, neoplasia, bone-marrow disease, renal failure and other clinical settings.
These categories identify where clinicians historically reached for immediate oxygen-carrying support. They do not compare diagnoses or prove effectiveness. The source explicitly permits overlapping classification, so its percentages must not be added as though they were mutually exclusive parts of one whole.
Central pattern: oxygen delivery as a bridge.
Across case narratives, support was used while hemorrhage was controlled, surgery was performed, vitamin K or immunosuppression acted, parasites were treated, compatible blood was prepared, diagnostics continued or endogenous erythropoiesis recovered.
Independent extraction
What appears in the 146 printed vignettes.
| Treatment sequence | Printed cases | Share of 146 |
|---|---|---|
| Oxyglobin only | 109 | 74.7% |
| Oxyglobin then whole blood | 23 | 15.8% |
| Oxyglobin then packed RBCs | 11 | 7.5% |
| Whole blood then Oxyglobin | 2 | 1.4% |
| Packed RBCs then Oxyglobin | 1 | 0.7% |
The printed 72-hour fields mark 129 cases as survived, 10 as died and 7 as not available. These numbers must not be published as an efficacy or survival rate. The vignettes were selected for a manufacturer booklet, collected through an incentive-linked reporting program, and sometimes mark 72-hour survival even when the narrative later reports death at 3.5 or 4.5 days.
Clinical interpretation
Blood is a system. Oxygen delivery is a function.
Some narratives describe improvement after immediate oxygen-carrying support followed by whole blood or packed red cells. Others show why oxygen delivery alone could not control ongoing bleeding or supply every function of donor blood.
Complementary, not universal replacement.
Oxygen-carrying support may create time for definitive treatment. It does not by itself stop hemorrhage, supply platelets or clotting factors, treat cancer, suppress immune-mediated destruction or cure infection.
Measurement question
Why clinical appearance could improve while PCV barely changed.
Packed cell volume measures the fraction of blood occupied by red cells. Cell-free plasma hemoglobin is not counted as red-cell volume. The historical label also warned that dilution after a 30 mL/kg infusion could make PCV and red-cell count inaccurate measures of anemia for 24 hours.
Functional assessment therefore requires more than PCV alone: total hemoglobin, circulation, oxygen affinity and unloading, blood flow, tissue demand and clinical physiology all matter. This does not mean PCV is unimportant. It means the measurement must match the compartment and the clinical question.
Safety travels with efficacy
The archive cannot be presented as success-only evidence.
The booklet's historical prescribing information discusses circulatory overload, oliguria or anuria, uncertain repeat administration, unestablished safety in breeding or pregnant/lactating dogs, laboratory-test interference and adverse events. The FDA field-trial record includes discoloration findings, vomiting, raised central venous pressure, tachypnea, dyspnea and pulmonary edema among reported events.
For exact controlled-trial claims and adverse-event frequencies, use the official FDA Freedom of Information summary, not OCR from the booklet.
Methodological limits
What the archive cannot establish.
Concomitant surgery, donor blood, medications and fluids prevent causal attribution from individual narratives.
The booklet presents selected cases from an incentive-linked collection program.
Many fields are missing, and a 72-hour status does not establish durable recovery.
The booklet alternates between n=885 and n=883 and gives conflicting IMHA counts and percentages.
Every clinical record in this booklet concerns dogs. It supplies no direct evidence for other species or humans.
Oxyglobin findings do not transfer automatically to BHOC formulation, dosing, safety, efficacy or approval.
Research value
What this source contributes to Precision Oxygen Therapeutics.
The archive is most valuable as a historical clinical map: it shows where immediate oxygen-carrying capacity was operationally relevant, which definitive treatments followed, which measurements were difficult to interpret and where donor blood remained necessary.
For BHOC research, it supports three questions: when oxygen support can create time for definitive treatment; which endpoints best capture function when PCV does not include plasma hemoglobin; and which canine observations justify, but never replace, species-specific development.
Do not claim: 129/146 as a survival rate; universal compatibility across species; absence of reactions or risks; control of bleeding or the underlying disease; repeat-dose safety; or efficacy in BHOC, other animals or humans.